Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

Podobne zapisy

• Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D
  od: DeJong, Colette, i wsp.
  Wydane: (2019)
• Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
  od: Tseng, Chien-Wen, i wsp.
  Wydane: (2020)
• Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D
  od: Yazdany, Jinoos, i wsp.
  Wydane: (2018)
• Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans
  od: Kazi, Dhruv S., i wsp.
  Wydane: (2017)
• Medicare Part D plans’ coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease
  od: Tseng, Chien-Wen, i wsp.
  Wydane: (2017)